How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI ...

Calling consciousness an "entropic engine" points to something psychologically obvious: selfhood costs energy. Maintaining a stable "me" model across time, contexts, and internal contradictions ...

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...

Summary In this episode of The Defenders Log, Paul Mockapetris, the architect of DNS, discusses the evolving role of the Domain Name System from a simple directory to a sophisticated security tool. He ...

"We've worked on TPUs since 2014 ... a long time before AI was fashionable," Thomas Kurian said at the Fortune Brainstorm AI ...

1. Risk: AI Monoculture (Shared Blind Spots). This is the most critical and overlooked systemic vulnerability. Building your ...

AgentLISA, the leading Agentic Security Operating System for Web3, today announced PaymentShield, a comprehensive ...

Calling for a revival of the concept of a co-operative commonwealth as a “solidarity stack” to reshape AI, he added: “Integrity can be world changing … we can show the co-operative principles by ...

In this Monday edition of quantum computing news, we look at a new push by SEALSQ ($LAES) to build silicon-based quantum systems, Xanadu’s early ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...